The STING-induced type I IFNs also activate NK-cells, stimulating them to attack tumor cells, thus releasing tumor antigens for myeloid presentation and enabling the priming of a new T-cell response in a now immune-permissive environment [14]. The gene discussed is STING1; the disease is neoplasm.